Tasigna 200 mg Capsule

Tasigna 200 mg Capsule contains nilotinib, a targeted anticancer medicine used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is a tyrosine kinase inhibitor that blocks the abnormal BCR-ABL protein involved in leukemia cell growth. The capsule is taken orally under the direction of a qualified healthcare professional.

BUY NOW

Category Novartis Healthcare Pvt Ltd

Description

Nilotinib works by binding to the BCR-ABL kinase and inhibiting signals that promote the growth of abnormal leukemia cells. Tasigna 200 mg is supplied as a hard gelatin capsule containing 200 mg of nilotinib and is intended for oral administration. The product should be taken on an empty stomach according to the prescribing physician’s instructions to support consistent drug absorption. Treatment and monitoring should be managed by a physician experienced in the diagnosis and treatment of chronic myeloid leukemia.

Technical Specification

Specification	Details
Active Ingredient	Nilotinib 200 mg
Dosage Form	Hard Capsule
Therapeutic Class	Protein-Tyrosine Kinase Inhibitor
Indication	Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Capsule Size	Size 0
Storage	Below 30°C

Product Also Known As

Tasigna 200 mg, Tasigna Nilotinib 200 mg Capsule, Nilotinib 200 mg Capsule, Nilotinib Hard Capsule, Tasigna Oncology Capsule, Nilotinib Anticancer Capsule